Antidote-controlled antithrombotic therapy targeting factor IXa and von willebrand factor

Annals of the New York Academy of Sciences

Volumn 1175, Issue , 2009, Pages 61-70

  Becker, Richard C ^a,d   Oney, Sabah ^b   Becker, Kristian C D ^c   Sullenger, Bruce ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antithrombotic; Aptamers; Oligonucleotide

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIDOTE; APTAMER; BLOOD CLOTTING FACTOR 9A; CLOPIDOGREL; COLLAGEN; GLYCOPROTEIN IB ALPHA; OLIGONUCLEOTIDE; RB 006; RB 007; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANTICOAGULANT THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG PROTEIN BINDING; HUMAN; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN TARGETING; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; UNSPECIFIED SIDE EFFECT;

EID: 70349469320     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05017.x     Document Type: Conference Paper

References (46)

1. Tuerk, C. L. Gold. 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249 : 505 510.
2. White, R.R., B.A. Sullenger C.P. Rusconi. 2000. Developing aptamers into therapeutics. J. Clin. Invest. 106 : 923 928.
3. Hermann, T. D.J. Patel. 2000. Adaptive recognition by nucleic acid aptamers. Science 287 : 820 825.
4. Patel, D.J., A.K. Suri, F. Jiang, et al. 1997. Structure, recognition and adaptive binding in RNA aptamer complexes. J. Mol. Biol. 272 : 645 664.
5. Ringquist, S., T. Jones, E.E. Snyder, et al. 1995. High-affinity RNA ligands to Escherichia coli ribosomes and ribosomal protein S1: comparison of natural and unnatural binding sites. Biochemistry 34 : 3640 3648.
6. Rusconi, C.P., E. Scardino, J. Layzer, et al. 2002. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419 : 90 94.
7. Layzer, J.M. B.A. Sullenger. 2007. Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection. Oligonucleotides 17 : 1 11.
8. Becker, R.C. F. Andreotti. 2006. Preoteomics, metabolomics and progenitor cells in acute coronary syndromes. J. Thromb. Thrombolysis 22 : 85 88.
9. Weiss, H.J. 1975. Platelet physiology and abnormalities of platelet function (first of two parts). N. Engl. J. Med. 293 : 531 541.
10. Carvalho, D., C.O. Savage, C.M. Black, et al. 1996. IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J. Clin. Invest. 97 : 111 119.
11. Greco, N.J. G.A. Jamieson. 1991. High and moderate affinity pathways for alpha-thrombin-induced platelet activation. Proc. Soc. Exp. Biol. Med. 198 : 792 799.
12. Seiler, S.M., H.J. Goldenberg, I.M. Michel, et al. 1991. Multiple pathways of thrombin-induced platelet activation differentiated by desensitization and a thrombin exosite inhibitor. Biochem. Biophys. Res. Commun. 181 : 636 643.
13. Szasz, R. G.L. Dale. 2002. Thrombospondin and fibrinogen bind serotonin-derivatized proteins on COAT-platelets. Blood 100 : 2827 2831.
14. Dale, G.L. 2005. Coated-platelets: an emerging component of the procoagulant response. J. Thromb. Haemost. 3 : 2185 2192.
15. Moers, A., B. Nieswandt, S. Massberg, et al. 2003. G13 is an essential mediator of platelet activation in hemostasis and thrombosis. Nat. Med. 9 : 1418 1422.
16. Freedman, J.E. 2005. Molecular regulation of platelet-dependent thrombosis. Circulation 112 : 2725 2734.
17. Hansson, G.K., P. Libby, U. Schonbeck, et al. 2002. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. 91 : 281 291.
18. Yamashita, A., Y. Asada, H. Sugimura, et al. 2003. Contribution of von Willebrand factor to thrombus formation on neointima of rabbit stenotic iliac artery under high blood-flow velocity. Arterioscler. Thromb. Vasc. Biol. 23 : 1105 1110.
19. Holmsen, H. H.J. Day. 1970. The selectivity of the thrombin-induced platelet release reaction: subcellular localization of released and retained constituents. J. Lab. Clin. Med. 75 : 840 855.
20. Holmsen, H., L. Robkin H.J. Day. 1979. Effects of antimycin A and 2-deoxyglucose on secretion in human platelets. Differential inhibition of the secretion of acid hydrolases and adenine nucleotides. Biochem. J. 182 : 413 419.
21. Kenney, D.M. F.C. Chao. 1978. Microtubule inhibitors alter the secretion of beta-glucuronidase by human blood platelets: involvement of microtubules in release reaction II. J. Cell Physiol. 96 : 43 52.
22. Cruz, M.A., J. Chen, J.L. Whitelock, et al. 2005. The platelet glycoprotein Ib-von Willebrand factor interaction activates the collagen receptor alpha2beta1 to bind collagen: activation-dependent conformational change of the alpha2-I domain. Blood 105 : 1986 1991.
23. Ruggeri, Z.M., J.N. Orje, R. Habermann, et al. 2006. Activation- independent platelet adhesion and aggregation under elevated shear stress. Blood 108 : 1903 1910.
24. Yap, C.L., S.C. Hughan, S.L. Cranmer, et al. 2000. Synergistic adhesive interactions and signaling mechanisms operating between platelet glycoprotein Ib/IX and integrin alpha IIbbeta 3. Studies in human platelets ans transfected Chinese hamster ovary cells. J Biol Chem. 275 : 41377 41388.
25. Oney, S., S.M. Nimjee, J. Layzer, et al. 2007. Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. Oligonucleotides 17 : 265 274.
26. Monroe, D.M. 2002. Platelets and thrombin generation. Arterioscler. Thromb. Vasc. Biol. 22 : 1381 1389.
27. Komiyama, Y., A.H. Pedersen W. Kisiel. 1990. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. Biochemistry 29 : 9418 9425.
28. Broze, G.J., L.A. Warren, W.F. Novotny, et al. 1988. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 71 : 335 343.
29. Rapaport, S.I. 1991. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb. Haemost. 66 : 6 15.
30. Monroe, D.M., M. Hoffman H.R. Roberts. 1996. Transmission of a procoagulant signal from tissue factor-bearing cells to platelets. Blood Coagulation Fibrinolysis 7 : 459 464.
31. Liu, L.W., T.K. Vu, C.T. Esmon, et al. 1991. The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity. J. Biol. Chem. 266 : 16977 16980.
32. Vu, T.K., D.T. Hung, V.I. Wheaton, et al. 1991. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64 : 1057 1068.
33. Vu, T.K., V.I. Wheaton, D.T. Hung, et al. 1991. Domains specifying thrombin-receptor interaction. Nature 353 : 674 677.
34. Brass, L.F., J.A. Hoxie D.R. Manning. 1993. Signaling through G proteins and G protein-coupled receptors during platelet activation. Thromb. Haemost. 70 : 217 223.
35. Brass, L.F., D.R. Manning, K. Cichowski, et al. 1997. Signaling through G proteins in platelets: to the integrins and beyond. Thromb Haemost. 78 : 581 589.
36. Pieters, J., T. Lindhout H.C. Hemker. 1989. In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. Blood 74 : 1021 1024.
37. Oliver, J.A., D.M. Monroe, H.R. Roberts, et al. 1999. Thrombin activates factor XI on activated platelets in the absence of factor XII. Arterioscler. Thromb. Vasc. Biol. 19 : 170 177.
38. Baglia, F.A. P.N. Walsh. 2000. Thrombin-mediated feedback activation of factor XI on the activated platelet surface is preferred over contact activation by factor XIIa or factor XIa. J. Biol. Chem. 275 : 20514 20519.
39. Scandura, J.M. P.N. Walsh. 1996. Factor X bound to the surface of activated human platelets is preferentially activated by platelet-bound factor IXa. Biochemistry 35 : 8903 8913.
40. Franssen, J., I. Salemink, G.M. Willems, et al. 1997. Prothrombinase is protected from inactivation by tissue factor pathway inhibitor: competition between prothrombin and inhibitor. Biochem. J. 323 (Pt 1 33 37.
41. Rezaie, A.R. 2001. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. Blood 97 : 2308 2313.
42. Lawson, J.H., M. Kalafatis, S. Stram, et al. 1994. A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem. 269 : 23357 23366.
43. Dyke, C.K., R.C. Becker, N.S. Kleiman, et al. 2002. First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. Circulation 105 : 2385 2391.
44. Dyke, C.K., S.R. Steinhubl, N.D. Kleiman, et al. 2006. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation 114 : 2490.
45. Chan, M.Y., M.G. Cohen, C.K. Dyke, et al. 2008. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 117 : 2865 2874.
46. Chan, M.Y., C.P. Rusconi, J.H. Alexander, et al. 2008. A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. J. Thromb. Haemost. 6 : 789 796.